Press Releases

Date Title and Summary
Toggle Summary Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal
Toggle Summary Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome
REDWOOD CITY, Calif. , Oct. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent (9,782,416) from the U.S.
Toggle Summary Soleno Therapeutics Announces 1-for-5 Reverse Stock Split
Previously approved reverse stock split to be implemented on Friday, October 6, 2017 REDWOOD CITY, Calif. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today
Toggle Summary Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has received scientific advice  from the Committee for Medicinal
Toggle Summary Soleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial of DCCR for Treatment of Prader-Willi Syndrome
Updated Data Highlighted in Poster Presentation at 10 th International Meeting of Pediatric Endocrinology Phase III Study Expected to Begin by End of 2017 REDWOOD CITY, Calif. , Sept. 15, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company
Toggle Summary Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR in Treatment of Prader-Willi Syndrome
Protection of Associated Claims into 2035 REDWOOD CITY, Calif. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent
Toggle Summary Soleno Therapeutics Announces CFO Transition
David O’Toole to Depart Company ; Interim CFO Appointed and Search for New CFO Initiated REDWOOD CITY, Calif. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Completed Successful FDA Meeting for DCCR in Prader-Willi Syndrome Preparing to begin Phase III program by the end of the year Monetized Non-Strategic Assets Through Sale of NeoForce, Inc. Subsidiary REDWOOD CITY, Calif. , Aug. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.
Toggle Summary Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare, Inc.
REDWOOD CITY, Calif. , July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the sale of one of its non-strategic subsidiaries, NeoForce, Inc.
Toggle Summary Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome
Positive guidance received on key elements of Phase III program Company expects to initiate pivotal Phase III clinical trial by year-end 2017 DCCR has orphan designation for the treatment of PWS in the US REDWOOD CITY, Calif. , July 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.